Posted by Dale Buss on December 6, 2012 09:01 AM
Apple plans limited US manufacturing as it lands back in court with Samsung and baffles Eric Schmidt.
Starbucks agrees to pay more UK tax, capitulating to criticism.
Rolls-Royce is caught in bribery probe in UK.
AmEx works on social engagement that closes the loop with consumers.
AT&T is on track for record smartphone sales.
Barclays Africa is sold to Absa in $2.1 billion transaction.
Bob Marley trademark spat settled as 'relaxation drink' comes under fire.
Deutsche Bank is probed by SEC.
Dish will start selling mobile phones at its Blockbuster movie rental stores.Continue reading...
Posted by Dale Buss on November 30, 2012 09:02 AM
Facebook details ding Zynga shares as partnership ends.
CNN needs more vibrancy in programming, incoming CEO Jeff Zucker says.
Lipitor generic cholesterol pill production halted by Ranbaxy following glass contamination.
Amazon tops Walmart with wealthy Americans, study says.
AT&T named best 4G network in Consumer Reports annual ranking, but places last for voice/text quality to #1 Verizon.
Chevrolet partners with Dailybreak for holiday push.
Chuck E. Cheese sees revamped mascot lose consumer appeal.
Cool Whip breaks new ground with frosting.
Duke Energy forces out CEO in settlement.Continue reading...
Posted by Dale Buss on August 1, 2012 09:01 AM
Apple and Samsung trade jabs as their high-stakes patent trial begins in San Francisco.
Avon opens talks to settle bribery charges.
BMW warns about tougher market conditions.
Bud Light Premium helps AB InBev sell less beer for more.
Coach suffers from competition from Michael Kors and other handbag purveyors.
Ford brand loyalty validated by new ranking.
Gap fall kids campaign continues bright color theme.
Google buys Wildfire social marketing firm.
Heineken invites creatives to redefine draught beer experience.Continue reading...
Posted by Mark J. Miller on May 10, 2012 12:22 PM
Lipitor may be good for folks for helping lower blood cholesterol, but it is also extremely good at making money. Its manufacturer, Pfizer, raked in $12.9 billion annually at Lipitor’s peak, but those cash-cow days when Lipitor was the world's top-selling prescription drug are long gone. More generally known as Atorvastatin, it became a generic back at the end of November.
When a drug goes generic, drug companies generally give up on it right away and move on to the next thing that can potentially rake in the dough. But Pfizer didn’t want to do that. Lipitor had brought in so much, the company was hoping that it could find a way that it could continue to be a revenue stream, including its Lipitor for You patient program, even though Walmart jumped on the generic version as soon as it could do so. Now, don't bother asking your doctor if Lipitor is right for you.Continue reading...
Posted by Dale Buss on May 10, 2012 09:03 AM
A&P to make CEO its spokesman in new marketing campaign.
Bed Bath & Beyond sees novelty in buying Cost Plus.
Brad Pitt is the new face of Chanel No. 5.
Burger King spurs sales with turnaround efforts.
Cadillac to debut instrument console that functions like an iPad.
Cisco sees grim outlook for tech sector.
Coca-Cola redefines its marketing around Super Bowl, and signs Danica Patrick as ambassador.Continue reading...
Posted by Dale Buss on May 2, 2012 09:00 AM
Facebook faces doubts by advertisers as it gears up for IPO roadshow.
Lifetime unveils new logo and tagline.
BlackBerry launches "Touch Awesomeness" campaign, test keyboardless version to challenge Apple.
Apple files for touch-based music-sharing patent.
CNN delivers lowest monthly ratings in a decade.
CVS succeeds in grabbing drugstore customers from Walgreens.
Chesapeake Energy board crimps CEO's power.Continue reading...
Posted by Barry Silverstein on February 22, 2012 01:25 PM
Battling counterfeit products is one of a brand's biggest headaches. More often than not, counterfeiting strikes luxury and accessory brands, since it is easier to sell fake branded handbags, shoes, and clothes online and in flea markets and bazaars around the world. But what about when buying a knock-off has life-or-death implications?
Fake products are penetrating an even more serious category than luxury goods — pharmaceuticals. America's Food and Drug Administration just announced the findings of the agency’s investigation of fake vials of the cancer drug Avastin that have showed up in California, Illionis, and Texas.
The FDA's tests indicated the vials did not contain Avastin's active ingredient, and traced the phony drug to the U.K. via a distributor in Tennessee. Reuters reported that the fake Avastin apparently originated in Cairo, Egypt and went from there through Switzerland to Britain. While the FDA was warned about the products by British officials late last year, it only confirmed that they were counterfeit last week. Cancer patients and medical practitioners, understandably, are up in arms.Continue reading...
Posted by Mark J. Miller on December 1, 2011 02:59 PM
The drug Lipitor has made Pfizer so much dough that it isn’t planning to just turn its attention to newer products now that the drug can be sold generically as of Wednesday, according to the Associated Press.
The problem is that Pfizer doesn’t have anything new that can make up for the $11 billion that Lipitor brings in, the AP points out, so it is doing everything it can to hang onto the customers it has.
The AP has it that when a drug goes generic, the revenue that is has been pulling in from that drug generally disappears for the most part within a year, but Pfizer has bought itself about six months by “devis(ing) discounts and incentives for patients, insurers and companies that process prescriptions” that will “make the brand name drug about as cheap as or cheaper than the generics.”Continue reading...